

Supplementary Table S3: Univariate OS Analysis

Variables	Pt#	Death#	Median OS (months; 95%CI)	HR (95%CI)	Pvalue*
Whole Cohort	199	55	NR		
Age at Diagnosis (5-year increase)				1.12(0.98-1.28)	0.087
Charlson Score (12 missing) (1-unit increase)				1.13(0.93-1.38)	0.22
NACT Cycle Group					
3	73	21	33.3(27-NE)	1	0.008
4	70	13	NR	0.57(0.28-1.14)	
>=5	56	21	28.9(19.7-NE)	1.64(0.89-3)	
4	70	13	NR	1	0.008
3	73	21	33.3(27-NE)	1.76(0.88-3.52)	
>=5	56	21	28.9(19.7-NE)	2.88(1.43-5.77)	
Histology					
Others	16	8	23.6(19.8-29.5)	1	0.034
High Grade Serous	183	47	NR	0.45(0.21-0.96)	
Stage					
III	66	15	NR	1	0.659
IV	133	40	NR	1.14(0.63-2.07)	
BRCA					
No mutation	139	46	33.3(28.9-NE)	1	0.009
BRCA1/2 Mutation	30	1	NR	0.09(0.01-0.65)	
Not tested	30	8	NR	1.18(0.56-2.5)	
NACT Regimen (12 missing)					
Paclitaxel Weekly/ Carboplatin	134	41	NR	1	0.765
Others	53	11	NR	0.9(0.46-1.76)	
NACT Indication***					
Patient factors	60	22	36.3(20.2-NE)	1	0.053
Disease factors	139	33	NR	0.59(0.34-1.01)	
Response on Imaging after 2-3 NACT Cycles					
Response	181	48	NR	1	0.035
No response/progression	18	7	29.5(14.8-29.5)	2.31(1.04-5.14)	
Optimal Debulking					
No	18	8	36.3(13.8-NE)	1	0.286
Yes	181	47	NR	0.67(0.31-1.41)	
CGR					
No	60	Sup	33.3(20.1-NE)	1	0.003
Yes	139	30	NR	0.46(0.27-0.78)	
Adjuvant Therapy (4 missing)**					

No	15	5	1	0.418
Yes	180	49	0.72(0.33-1.60)	

*Log-rank test is applied to obtain p-value for categorical variables and CoxPH model is used to obtain p-value for continuous variables.

**CoxPH model with counting process is modeled for time dependent variable.

*** Patient factors include Aletti Score, comorbidity, venous thromboembolism, clinical trial, or other. Disease factors include Stage IV unresectable, extent of disease on imaging, extent of disease on laparoscopy, extent of disease requiring thoracic surgery.